Alnylam plans a move into ex-Vertex building in Cambridge; Immuno-oncology gets a stock index;

@FierceBiotech: High-flying immuno-oncology player Adaptimmune pitches $150M IPO. News | Follow @FierceBiotech

@JohnCFierce: Plotting a course for True North, biotech CEO steps up with a $35M round. Report | Follow @JohnCFierce

> Alnylam ($ALNY) is moving into Vertex's ($VRTX) former facilities at Kendall Square in Cambridge, MA, according to the Boston Business Journal. The move will more than double the size of its HQ as Alnylam moves ahead with clinical development programs. The current tenants are expected to move out by May 2018. Story

> The recent boom in immuno-oncology has helped a host of companies make their way onto Wall Street, and investor Brad Loncar has created an index to keep tabs on the fast-growing field. More

> Waltham, MA-based Interleukin Genetics announced the appointment of Mark Carbeau as CEO and director. Ex-CEO Dr. Kenneth Kornman will continue to serve as president, CSO and director. Release

> After years of delay, Shire ($SHPG) says it has finally identified a clear regulatory path for SHP465, an oral treatment for ADHD in adults. Item (PDF)

Medical Device News

@FierceMedDev: Check out the top med tech companies of 2014. Feature | Follow @FierceMedDev

@VarunSaxena2: Experts: Stent retrieval devices to play larger role in treatment of stroke. Story | Follow @VarunSaxena2

@EmilyWFierce: Natera ropes in $55M with eye on cancer Dx. FierceDiagnostics article | Follow @EmilyWFierce

> Miniaturized skin cancer device emerges as alternative to surgery. Article

> J&J's Ethicon gets FDA clearance to use Evarrest patch for liver surgery. Report

Pharma News

@FiercePharma: Medtronic settles DoJ charges for $4.1M on spinal device sales in Malaysia, China. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Layoffs for manufacturing units at Amgen, Novartis contributed to sizable cuts last year. Check out the new feature | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: CEO Dekkers' legacy at Bayer? Embracing risk, à la its American rivals. Report | Follow @CarlyHFierce

> No real rationale for rising cancer drug prices, JAMA researchers conclude. Report

> Watch out, Valeant. Concordia's joining the buy-to-grow pharma business. Article

Drug Delivery News

> Gold nanoparticles deliver RNA to the brain to suppress cancer genes. Story

> Developer of Botox lotion files for $58M IPO. Item

> Researchers take aim at childhood neuroblastoma with targeted nanoparticles. More

> Actavis' drug delivery-focused spinoff on the prowl for acquisitions. Report

> AstraZeneca gets FDA nod for alternative administration of oral heart med. Article

Pharma Manufacturing News

> AMRI moves forward with plan to close Wales API plant, cut 62 jobs. Item

> Baxter recalls more than half a million units of saline. News

> North Carolina compounder is closed and its products are recalled. Story

> India's Mankind Pharma investing $16M in API plant. Article

> UAE drug distributor building a $20M plant in Dubai. Report

Pharma Asia News

> Australia-China researchers eye Asian stroke drug for Alzheimer's disease. Story

> South Korea struggles with healthcare needs of elderly. Report

> Second quarter pharma market outlooks for pan-Asia mixed, India promising. Story

> India's Mankind sees 15th product plant online this year. Article

> Sirtex Medical oncology play still has some thunder Down Under. More

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.